sign in sign up
<<
Home , Certolizumab pegol, Golimumab, Omalizumab

NICE Technology Appraisals About Medicines: Formulary Adherence Checklist

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Last updated 08-Mar-16

Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as Adherence of local formulary to NICE (TA) Release indicated by NICE Titles are hyperlinks to Date of local Time to Yes N/A Date of local full guidance (mark 'x' if (mark 'x' if decision Due implement decision Made applicable) applicable) (90 days) (days) 2015-16 01/06/2015 (Xolair) is recommended as a possible treatment for people aged 12 years and over with severe chronic spontaneous urticaria if:

•a doctor has objectively diagnosed the condition as severe •the condition has not improved with standard treatment with TA339 - Omalizumab H1‑ or leukotriene antagonists for previously treated •the drug is stopped at or before the fourth dose if the condition has not X 30/08/2015 21/09/2015 112 chronic spontaneous responded urticaria •the drug is stopped at the end of a course of treatment (6 doses) if the condition has responded, and is only restarted if the condition comes back •the drug is given by a secondary care specialist in dermatology, immunology or allergy.

1 01/06/2015 (Stelara) is recommended as a possible treatment, alone or with a drug called , for adults with active when treatment with non-biological disease-modifying antirheumatic drugs (or TA 340 - Ustekinumab DMARDS) has not worked well enough if: for treating active psoriatic arthritis (rapid X 30/08/2015 20/07/2015 49 •treatment with tumour necrosis factor (TNF) alpha inhibitors is not suitable for review of technology them, or appraisal guidance 313 •the person has had a TNF alpha inhibitor before. Treatment with ustekinumab should be stopped after 24 weeks if it is not 1 working well enough. 01/06/2015 TA341 - Apixaban for the treatment and secondary prevention Apixaban (Eliquis) is recommended as an option for treating and preventing of deep vein thrombosis X 30/08/2015 01/06/2015 0 recurrent deep vein thrombosis or pulmonary embolism. and/or pulmonary embolism- technology appraisal guidance 1 01/06/2015 (Entyvio) is recommended as a possible treatment for adults with moderate to severe .

People should be able to have the treatment until it stops working or surgery is TA342 - Vedolizumab needed. Their condition should be assessed 12 months after they started for treating moderately taking vedolizumab. If they still have symptoms but it is clear that the treatment to severely active is helping, they can continue to have it. If they no longer have symptoms, X 30/08/2015 19/10/2015 140 ulcerative colitis- treatment could be stopped, and later restarted if symptoms return. technology appraisal guidance People who continue to take vedolizumab should be assessed at least every 12 months to see whether the treatment is working well enough for them to carry on taking it. 1 01/06/2015 (Gazyvaro), given with a drug called chlorambucil, is recommended as a possible treatment for adults with untreated chronic TA343 - Obinutuzumab lymphocytic leukaemia only if: in combination with chlorambucil for •they have other conditions that make full-dose fludarabine unsuitable for them X 30/08/2015 17/07/2015 46 untreated chronic and lymphocytic leukaemia •bendamustine is not suitable for them. – guidance What does this mean for me? 1 01/06/2015 Ofatumumab (Arzerra) given with a drug called chlorambucil is recommended TA344 - Ofatumumab in as a possible treatment for people with untreated chronic lymphocytic combination with leukaemia if treatments containing fludarabine or bendamustine are not chlorambucil or suitable. X 30/08/2015 15/09/2015 106 bendamustine for untreated chronic Ofatumumab (with chlorambucil) should be available on the NHS within 3 lymphocytic leukaemia 1 months of the guidance being issued. 01/07/2015 Naloxegol (Moventig) is recommended as a possible treatment for people with TA345 - Naloxegol for opioid induced constipation that has had an inadequate response to laxatives. treating opioid‑induced X 29/09/2015 19/10/2015 110 constipation

1 01/07/2015 (Eylea) injections are recommended as a possible treatment for TA346 - Aflibercept for some people with sight problems caused by diabetic macular oedema, as treating diabetic explained below. X 29/09/2015 24/08/2015 54 macular oedema

1 TA347 - Nintedanib for 01/07/2015 Nintedanib (Vargatef), given with a drug called docetaxel, is recommended. It previously treated is a possible treatment for people with a certain type (adenocarcinoma) of locally advanced, locally advanced, metastatic or locally recurrent non-small-cell lung cancer metastatic, or locally that has got worse after previous chemotherapy. X 29/09/2015 24/08/2015 54 recurrent non‑small‑cell lung cancer 1 TA348 - for 01/07/2015 Everolimus (Certican) is not recommended for preventing organ rejection in preventing organ people having a liver transplant. rejection in liver X 29/09/2015 24/08/2015 54 transplantation 1 01/07/2015 Dexamethasone intravitreal implant (Ozurdex) is recommended as a possible TA349 - treatment for people with sight problems caused by diabetic macular oedema Dexamethasone if: intravitreal implant for X 29/09/2015 24/08/2015 54 treating diabetic •there is an artificial lens in the eye to be treated, and macular oedema •their diabetic macular oedema has not improved with non‑corticosteroid treatment, or such treatment is not suitable for them. 1 Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as Adherence of local formulary to NICE (TA) Release indicated by NICE Titles are hyperlinks to Date of local Time to Yes N/A Date of local full guidance (mark 'x' if (mark 'x' if decision Due implement decision Made applicable) applicable) (90 days) (days) 2015-16 01/07/2015 (Cosentyx) is recommended as a possible treatment for people with plaque if:

•standard assessments show that their psoriasis is severe and is affecting their quality of life, and TA350 - Secukinumab •their psoriasis has not improved with other treatments including , for treating moderate to methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or they X 29/09/2015 18/05/2015 -44 severe plaque psoriasis have had side effects with these treatments in the past or there is a reason why they cannot have them. Treatment with secukinumab should be stopped after 12 weeks if the psoriasis does not improve enough according to standard measures.

1 01/07/2015 NICE is unable to make a recommendation about the use in the NHS of TA351 - Cangrelor for cangrelor for reducing atherothrombotic events in people undergoing reducing percutaneous coronary intervention or awaiting surgery requiring interruption atherothrombotic of anti-platelet therapy because no evidence submission was received from events in people The Medicines Company undergoing percutaneous coronary X 29/09/2015 21/09/2015 82 intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)

1 01/08/2015 TA352 Vedolizumab for Vedolizumab (Entyvio) is recommended. It is a possible option for adults with treating moderately to moderate to severe Crohn’s disease if a type of treatment called a tumour severely active Crohn's X 30/10/2015 19/10/2015 79 necrosis factor (TNF) alpha inhibitor isn’t suitable or hasn’t worked well disease after prior enough. therapy 1 TA353 Bevacizumab 01/08/2015 NICE is unable to make a recommendation about the use in the NHS of for treating relapsed, bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, platinum resistant fallopian tube or primary peritoneal cancer because no evidence submission epithelial ovarian, was received from Roche Products for the technology. X 30/10/2015 21/09/2015 51 fallopian tube or primary peritoneal cancer (terminated 1 appraisal) 01/08/2015 Edoxaban (Lixiana) is recommended as an option for treating and TA354 Edoxaban for treating and for preventing recurrent deep vein thrombosis or pulmonary embolism. preventing deep vein X 30/10/2015 14/12/2015 135 thrombosis and pulmonary embolism 1 01/10/2015 for treating advanced melanoma after disease TA357 progression with Pembrolizumab for treating advanced X 30/12/2015 26/10/2015 25 melanoma after disease progression with ipilimumab 1 TA355 Edoxaban for 01/09/2015 Edoxaban for preventing stroke and systemic embolism in people with preventing stroke and non‑valvular atrial fibrillation systemic embolism in X 30/11/2015 14/12/2015 104 people with non‑valvular atrial 1 fibrillation 01/09/2015 Ruxolitinib for treating polycythaemia vera (terminated appraisal) TA356 Ruxolitinib for treating X 30/11/2015 26/10/2015 55 polycythaemia vera (terminated appraisal) 1 TA358 Tolvaptan for 01-Oct-15 Tolvaptan (Jinarc) is recommended as a possible treatment for people treating autosomal with autosomal dominant polycystic kidney disease if: dominant polycystic kidney disease • they have chronic kidney disease stage 2 or 3 at the start of X 31/12/2015 18/01/2016 109 . treatment and • there is evidence of rapidly progressing disease. 1 TA359 Idelalisib for 01-Oct-15 Idelalisib (Zydelig), given with a drug called , is recommended treating chronic as a possible treatment for adults with: lymphocytic leukaemia • untreated chronic lymphocytic leukaemia, only if they have certain X 31/12/2015 22/02/2016 91 . genetic chatacteristics • chronic lymphocytic leukaemia, only if it has been treated but has . come back within 2 years. 1 TA360 Paclitaxel as 01-Oct-15 albumin-bound nanoparticles in combination with gemcitabine for X 31/12/2015 23/11/2015 53 previously untreated metastatic pancreatic cancer 1 TA361 Simeprevir in 01-Oct-15 combination with sofosbuvir for treating genotype 1 or 4 chronic X 31/12/2015 23/11/2015 53 hepatitis C (terminated appraisal)

1 Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as Adherence of local formulary to NICE (TA) Release indicated by NICE Titles are hyperlinks to Date of local Time to Yes N/A Date of local full guidance (mark 'x' if (mark 'x' if decision Due implement decision Made applicable) applicable) (90 days) (days) 2015-16 TA362 Paclitaxel as 01-Oct-15 albumin-bound nanoparticles with carboplatin for untreated non-small- X 31/12/2015 23/11/2015 53 cell lung cancer (terminated appraisal)

1 TA363 25-Nov-15 Ledipasvir-sofosbuvir (Harvoni) is recommended as a possible treatment for Ledipasvir–sofosbuvir adults with some types (called genotypes) of chronic hepatitis C. for treating chronic hepatitis C X 23/02/2016 16/12/2015 21

1 TA364 Daclatasvir for 25-Nov-15 Daclatasvir (Daklinza) is recommended as a possible treatment for adults with treating chronic some types (called genotypes) of chronic hepatitis C, depending on their level hepatitis C of fibrosis. It is taken with sofosbuvir or peginteron alfa, and sometimes with a drug called ribavirin. X 23/02/2016 16/12/2015 21

1 TA365 25-Nov-15 Ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) Ombitasvir–paritaprevir is recommended as a possible treatment for adults with some types (called –ritonavir with or genotypes) of chronic hepatitis C. It is sometimes taken with ribavirin. without dasabuvir for treating chronic X 23/02/2016 16/12/2015 21 hepatitis C

1 TA366 Pembrolizumab 25-Nov-15 Pembrolizumab (Keytruda) is recommended. This drug is a possible treatment for advanced melanoma for adults with melanoma that: not previously treated with ipilimumab •can’t be completely removed by surgery or has spread to other parts of the body X 23/02/2016 16/12/2015 21 •has not been treated with ipilimumab before.

1 TA367 Vortioxetine for 25/11/2015 Vortioxetine (Brintellix) is recommended as a possible treatment for adults treating major having a first or recurrent major depressive episode, if the current episode has depressive episodes not responded to 2 antidepressants. 23/02/2016

1 TA368 for 25/11/2015 Apremilast (Otezla) is not recommended for treating moderate to severe treating moderate to chronic plaque psoriasis in adults whose psoriasis has not improved with other severe plaque psoriasis treatments, or they have had side effects with these treatments in the past or X 23/02/2016 16/12/2015 21 there is a reason why they cannot have them 1 31/12/2015 Ciclosporin (Ikervis) is recommended as a possible treatment for people with TA369 Ciclosporin for dry eye disease that has not improved despite treatment with artificial tears. treating dry eye disease that has not improved 30/03/2016 despite treatment with artificial tears 1 31/12/2015 Bortezomib (Velcade) is recommended as a possible treatment for adults with TA370 Bortezomib for mantle cell lymphoma that has not been treated before, if haematopoietic stem previously untreated cell transplantation is not suitable for them x 30/03/2016 04/02/2016 35 mantle cell lymphoma 1 TA371 Trastuzumab 31/12/2015 Trastuzumab emtansine (Kadcyla) is not recommended. This drug is for adults emtansine for treating with advanced HER2-positive breast cancer that has been treated before with HER2-positive, trastuzumab and a taxane (paclitaxel or docetaxel). unresectable locally advanced or metastatic x 30/03/2016 25/01/2016 25 breast cancer after treatment with trastuzumab and a 1 taxane 31/12/2015 Apremilast (Otezla) is not recommended for adults with active psoriatic arthritis when earlier treatment with disease-modifying antirheumatic drugs (DMARDS) has not worked well enough or isn’t suitable TA372 Apremilast for treating active psoriatic 30/03/2016 25/01/2016 25 arthritis

1 31/12/2015 (Orencia), (Humira), (Enbrel) and (RoActemra) are recommended as possible treatments for people with polyarticular juvenile idiopathic arthritis. TA373 Abatacept, adalimumab, Adalimumab and etanercept are recommended as possible treatments for etanercept and people with enthesitis-related juvenile idiopathic arthritis. x 30/03/2016 25/01/2016 25 tocilizumab for treating juvenile idiopathic Etanercept is recommended as a possible treatment for people with psoriatic arthritis juvenile idiopathic arthritis.

1 Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as Adherence of local formulary to NICE (TA) Release indicated by NICE Titles are hyperlinks to Date of local Time to Yes N/A Date of local full guidance (mark 'x' if (mark 'x' if decision Due implement decision Made applicable) applicable) (90 days) (days) 2015-16 31/12/2015 Erlotinib (Tarceva) is recommended as a possible treatment for people with locally advanced or metastatic non‑small‑cell lung cancer that has already been treated with non-targeted chemotherapy because of delayed confirmation of epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation status, if:

•their cancer tests positive for the EGFR‑TK mutation or TA374 Erlotinib and •it is not known if the cancer is EGFR‑TK mutation‑positive because of gefitinib for treating non- problems with the test, and small-cell lung cancer - the cancer is very likely to be EGFR‑TK mutation‑positive x 30/03/2016 25/01/2016 25 that has progressed - it responds to the first 2 cycles of treatment with erlotinib. after prior Erlotinib is not recommended for treating locally advanced or metastatic chemotherapy non‑small‑cell lung cancer that doesn’t test positive for the EGFR‑TK mutation.

Gefitinib (Iressa) is not recommended for treating non‑small‑cell lung cancer that has progressed after chemotherapy.

1 26/01/2016 Evidence-based recommendations on adalimumab (Humira), TA375 Adalimumab, etanercept (Enbrel), (Remicade, Remsima, Inflectra), etanercept, infliximab, (Cimzia), (Simponi), tocilizumab certolizumab pegol, (RoActemra) and abatacept (Orencia). These drugs are for people with golimumab, tocilizumab severe who have tried conventional DMARDs only and abatacept for but they have not worked. x 25/04/2016 04/02/2016 9 rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. 1 TA376 Radium-223 27/01/2016 Evidence-based recommendations on radium-223 dichloride (Xofigo) dichloride for treating for treating hormone-relapsed prostate cancer with bone metastases hormone-relapsed x 26/04/2016 22/02/2016 26 prostate cancer with 1 bone metastases. 28/01/2016 Evidence-based recommendations on enzalutamide (Xtandi) for TA377 Enzalutamide treating metastatic, hormone-relapsed prostate cancer for people in for treating metastatic whom chemotherapy is not yet clinically indicated hormone-relapsed 27/04/2016 prostate cancer before chemotherapy is indicated. 1 TA378 Ramucirumab 27/01/2016 Evidence-based recommendations on ramucirumab (Cyramza) for for treating advanced treating advanced gastric cancer or gastro-oesophageal junction gastric cancer or adenocarcinoma previously treated with chemotherapy. gastro–oesophageal x 26/04/2016 22/02/2016 26 junction adenocarcinoma previously treated with 1 chemotherapy. 27/01/2016 Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis

TA379 Nintedanib for treating idiopathic X 26/04/2016 05/02/2016 9 pulmonary fibrosis.

1 27/01/2016 Evidence-based recommendations on panobinostat (Farydak) for TA380 Panobinostat for treating multiple myeloma after at least 2 previous treatments. treating multiple 26/04/2016 myeloma after at least 2 previous treatments. 1 27/01/2016 Evidence-based recommendations on olaparib (Lynparza) for the TA381 Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum- maintenance treatment sensitive ovarian, fallopian tube and peritoneal cancer in people whose of relapsed, platinum- relapsed disease has responded to platinum-based chemotherapy. sensitive, BRCA mutation-positive ovarian, fallopian tube x 26/04/2016 22/02/2016 26 and peritoneal cancer after response to second-line or subsequent platinum- based chemotherapy. 1 27/01/2016 NICE was unable to make recommendations on eltrombopag TA382 Eltrombopag for (Revolade) for severe aplastic anaemia refractory to treating severe aplastic immunosuppressive therapy because no evidence submission was anaemia refractory to received from , but will review this decision if the company x 26/04/2016 04/02/2016 8 immunosuppressive decides to make a submission therapy (terminated appraisal). 1 Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as Adherence of local formulary to NICE (TA) Release indicated by NICE Titles are hyperlinks to Date of local Time to Yes N/A Date of local full guidance (mark 'x' if (mark 'x' if decision Due implement decision Made applicable) applicable) (90 days) (days) 2015-16 01/02/2016 Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for TA383 TNF-alpha people with severe active or severe inhibitors for ankylosing non‑radiographic axial spondyloarthritis who have tried non‑steroidal spondylitis and non- anti‑inflammatory drugs (NSAIDs), but they have not worked. x 01/05/2016 radiographic axial spondyloarthritis.

1 18/02/2016 Evidence-based recommendations on (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

TA384 Nivolumab for treating advanced 18/05/2016 (unresectable or metastatic) melanoma

1 24/02/2016 Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

TA385 Ezetimibe for This guidance updates and replaces NICE technology appraisal treating primary guidance on ezetimibe for the treatment of primary (heterozygous- heterozygous-familial and familial and non-familial) hypercholesterolaemia (TA132). X 24/05/2016 24/02/2016 0 non-familial hypercholesterolaemia

1 19 22 Average % "Yes" % "N/A" implement time 47 (days) Adherence statistics for 40% 47% 48 2015-16